Comment
Author: Admin | 2025-04-28
Farxiga which is used for treating heart failure and type 2 diabetes., has several other brand drugs in the same treatment category and using the same active ingredient (Dapagliflozin). Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively. Drug Owner Drug Name Treatment Area Astrazeneca Ab Qtern (uses Dapagliflozin) Used for the treatment of type 2 diabetes mellitus in patients who have inadequate control with dapagliflozin. Bydureon used for improving glycemic control in patients with type 2 diabetes mellitus. Xigduo Xr (uses Dapagliflozin) used for managing type 2 diabetes mellitus when glycemic control is not achievable with other medications. Qternmet Xr (uses Dapagliflozin) Used for managing blood sugar levels in individuals with type 2 diabetes mellitus. Bydureon Pen used for improving glycemic control in patients with Type 2 diabetes, reducing food intake, delaying gastric motility, reducing body weight, and stimulating insulin release.Boehringer Ingelheim Tradjenta Used for treating type 2 diabetes, especially in patients with renal impairment and insufficient glycemic control.Cosette Welchol Used for lowering serum glucose levels in adults with type 2 diabetes mellitus and lowering cholesterol levels.Janssen Pharms Invokana used for the treatment of type 2 diabetes mellitus and reduction of cardiovascular and kidney-related risks. Invokamet Used for reducing the risk of kidney disease, cardiovascular events, and treating type 2 diabetes mellitus patients. Invokamet Xr used for treating type 2 diabetes and reducing the risk of kidney disease, cardiovascular events, and heart failure.Sb Pharmco Avandamet Used for managing and treating type 2 diabetes mellitus. Apart from brand drugs containing the same ingredient, some generics have also been filed for Dapagliflozin, Farxiga's active ingredient. Check the complete list of approved generic manufacturers for Farxiga About Farxiga Farxiga is a drug owned by Astrazeneca Ab. It is used for treating heart failure and type 2 diabetes. Farxiga uses Dapagliflozin as an active ingredient. Farxiga was launched by Astrazeneca Ab in 2014. Farxiga was approved by FDA for market use on 08 January, 2014. NCE-1 date: NCE-1 date also known as the four year date occurs four years after the original drug approval and marks the first opportunity for a generic manufacturer to file an ANDA with a Paragraph IV certification. This is the earliest point when generic competition might begin, provided the challenge is successful. Since the approval date for Farxiga is 08 January, 2014, its NCE-1 date is estimated to be 12 December, 2026. Treatment: Farxiga is used for treating heart failure and type 2 diabetes. Dosage: Farxiga is available in tablet form for oral use. Given below is detailed information on Dosage - Strength Dosage Form Availability Application Pathway 10MG TABLET
Add Comment